AbbVie is a pharmaceutical company that discovers, develops, and markets both biopharmaceuticals and small molecule drugs. The Company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C.

Employee Rating

3.7More
TypePublic
HQNorth Chicago, US
Founded2013
Size (employees)30,000 (est)+4%
Websiteabbvie.com
AbbVie was founded in 2013 and is headquartered in North Chicago, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at AbbVie

Richard Gonzalez

Richard Gonzalez

Chairman of the Board and Chief Executive Officer
Carlos Alban

Carlos Alban

Executive Vice President, Commercial Operations
Timothy Richmond

Timothy Richmond

Senior Vice President, Human Resources​
Azita Saleki-Gerhardt

Azita Saleki-Gerhardt

Senior Vice President, Operations
Karen Hale

Karen Hale

Vice President, Chief Ethics and Compliance Officer
Wulff-Erik von Borcke

Wulff-Erik von Borcke

President, Pharmacyclics
Show more

AbbVie Office Locations

AbbVie has offices in Singapore, Campoverde, Sligo, San Francisco and in 12 other locations
North Chicago, US (HQ)
1 Waukegan Rd
Cambridge, US
200 Sidney St
Barceloneta, PR
PR-2
Show all (16)
Report incorrect company information

AbbVie Financials and Metrics

AbbVie Revenue

Embed Graph
AbbVie's revenue was reported to be $25.64 b in FY, 2016 which is a 12.2% increase from the previous period.
USD

Revenue (Q3, 2018)

8.2b

Gross profit (Q3, 2018)

6.4b

Gross profit margin (Q3, 2018), %

77.7%

Net income (Q3, 2018)

2.7b

EBIT (Q3, 2018)

3.2b

Market capitalization (9-Nov-2018)

133.6b

Closing stock price (9-Nov-2018)

88.8

Cash (30-Sep-2018)

8.0b

EV

128.5b
AbbVie's current market capitalization is $133.6 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

18.8b20.0b22.9b25.6b

Revenue growth, %

6%15%12%

Cost of goods sold

4.6b4.4b4.5b5.8b

Gross profit

14.2b15.5b18.4b19.8b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

4.7b4.6b4.9b5.0b5.0b5.5b5.9b6.0b6.5b6.4b6.5b6.9b7.0b7.9b8.3b8.2b

Cost of goods sold

1.1b1.1b1.1b1.1b942.0m916.0m1.2b1.4b1.4b1.5b1.6b1.5b1.6b1.9b1.9b1.8b

Gross profit

3.6b3.5b3.8b3.9b4.1b4.6b4.8b4.6b5.0b4.9b4.9b5.4b5.4b6.0b6.3b6.4b

Gross profit Margin, %

77%76%77%78%81%83%80%77%78%77%75%78%77%76%77%78%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

9.6b8.3b8.4b5.1b

Accounts Receivable

3.9b3.7b4.7b4.8b

Inventories

1.2b1.1b1.7b1.4b

Current Assets

17.8b16.1b16.3b16.2b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

9.0b8.1b9.1b7.7b7.9b7.4b9.2b7.6b6.3b6.2b4.7b6.1b8.4b9.0b3.5b8.0b

Accounts Receivable

3.8b3.7b3.7b3.6b4.2b4.4b4.6b4.8b5.0b5.0b4.7b4.9b4.9b5.8b5.8b5.8b

Inventories

1.2b1.1b1.0b1.0b1.0b1.6b1.8b1.8b1.8b1.6b1.4b1.6b1.8b1.7b1.6b1.8b

Current Assets

16.5b17.3b17.8b17.6b15.4b16.9b17.9b16.6b16.8b16.3b15.5b17.0b18.9b20.4b13.8b18.5b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

4.1b1.8b5.1b6.0b

Inventories

(56.0m)(203.0m)(434.0m)(38.0m)

Accounts Payable

(426.0m)(193.0m)1.5b(1.2b)

Cash From Operating Activities

6.3b3.5b7.5b7.0b
Quarterly
USDY, 2018

EV/EBIT

40.7 x

Debt/Equity

-1 x

Financial Leverage

-22.7 x
Show all financial metrics

AbbVie Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Stem CentRxApril 28, 2016$5.80 b
Report incorrect company information

AbbVie Online and Social Media Presence

Embed Graph
Report incorrect company information

AbbVie News and Updates

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AbbVie Inc. of Class Action Lawsuit and Upcoming Deadline - ABBV

NEW YORK, Nov. 7, 2018 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AbbVie Inc. ("AbbVie" or the "Company") (NYSE: ABBV) and certain of its officers. The class action, filed in United States District Court, Northern District of Illinois, and...

AbbVie Announces HUMIRA® (adalimumab) Global Patent License with Momenta

NORTH CHICAGO, Ill., Nov. 6, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today patent license agreements with Momenta over its proposed biosimilar adalimumab product. Under the terms of the agreements, AbbVie will grant Momenta a non-exclusive license on specified dates to AbbVie's ...

Momenta Pharmaceuticals Announces Global Settlement with AbbVie to Enable Commercialization of M923, a Proposed Biosimilar to HUMIRA® (adalimumab)

CAMBRIDGE, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today announced that it has executed agreements with AbbVie Inc., providing license rights for the global launch of M923, Momenta’s proposed biosimilar to HUMIRA. Under the terms of the agreements and …

AbbVie Best-Seller Humira Shows Its Mortality

AbbVie Best-Seller Humira Shows Its Mortality

AbbVie sees hit to Humira sales from European competition

U.S. drugmaker AbbVie Inc on Friday lowered its overseas sales forecast for its top-selling medicine, Humira, as it agreed to larger-than-expected price cuts due to new European competition.

Humira biosimilars available at up to 80 percent discount in Europe: AbbVie

AbbVie Inc said on Friday rival biosimilar versions of its best-selling drug Humira were available in Europe at discounts ranging from 10 percent to 80 percent.
Show more
Report incorrect company information

AbbVie Company Life and Culture

Report incorrect company information

AbbVie Frequently Asked Questions

wdxefcqufszuzezftuxetqsqxt
  • When was AbbVie founded?

    AbbVie was founded in 2013.

  • Who are AbbVie key executives?

    AbbVie's key executives are Richard Gonzalez, Carlos Alban and Timothy Richmond.

  • How many employees does AbbVie have?

    AbbVie has 30,000 employees.

  • What is AbbVie revenue?

    Latest AbbVie annual revenue is $25.6 b.

  • What is AbbVie revenue per employee?

    Latest AbbVie revenue per employee is $854.6 k.

  • Who are AbbVie competitors?

    Competitors of AbbVie include Johnson & Johnson, Roche and Novartis.

  • Where is AbbVie headquarters?

    AbbVie headquarters is located at 1 Waukegan Rd, North Chicago.

  • Where are AbbVie offices?

    AbbVie has offices in Singapore, Campoverde, Sligo, San Francisco and in 12 other locations.

  • How many offices does AbbVie have?

    AbbVie has 16 offices.